PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? by Claud Grigg, Naiyer A. Rizvi

Get full text

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development by Jeffrey Sosman, Elad Sharon, Theresa LaVallee, Hussein A Tawbi, Ryan J Sullivan, Harriet M Kluger, Naiyer A Rizvi, David Feltquate

Get full text

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy by Kim A. Brogden, Deepak Parashar, Andrea R. Hallier, Terry Braun, Fang Qian, Naiyer A. Rizvi, Aaron D. Bossler, Mohammed M. Milhem, Timothy A. Chan, Taher Abbasi, Shireen Vali

Get full text

Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings by Benjamin Izar, Justin F Gainor, Mark M Awad, Codruta Chiuzan, Anjali Saqi, Catherine A Shu, Katja Schulze, Brian S Henick, Naiyer A Rizvi, Samyukta Mallick, Yohanna Georgis, Peter D Koch, Stephanie Izard, Robert F Garofano, Cheryl V Wong, Jessica Grindheim, Joshua R Sonett, Alison M Taylor

Get full text

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors by Toshihiko Doi, John A Thompson, Omid Hamid, Adi Diab, Siwen Hu-Lieskovan, Jeffrey Chou, Jeffrey S Wasser, Patrick A Ott, Jean-Philippe Spano, Willeke Ros, Alison Forgie, Wenjing Yang, Ferry A L M Eskens, Alberto A Chiappori, Eric Angevin, Naiyer A Rizvi, Cen Guo, Anthony B El-Khoueiry

Get full text

Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response Calculator Tool, and Challenges in Practice by Anjali Saqi, MD, MBA, Kevin O. Leslie, MD, Andre L. Moreira, MD, PhD, Sylvie Lantuejoul, MD, PhD, Catherine Ann Shu, MD, Naiyer A. Rizvi, MD, Joshua R. Sonett, MD, Kosei Tajima, MS, Shawn W. Sun, PharmD, Barbara J. Gitlitz, MD, Thomas V. Colby, MD

Get full text

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) by Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne J. Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm, Lawrence H. Schwartz, Boris Sepesi, Beow Yong Yeap, Naiyer A. Rizvi, Roy S. Herbst

Get full text

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors by Mario Sznol, Michael Yellin, Tibor Keler, Jose Lutzky, Amy Weise, Margaret K Callahan, Osama Rahma, Rachel E Sanborn, Alexander Starodub, Deepa S Subramaniam, Antonio Jimeno, Tracey Rawls, David A Reardon, Daniel C Cho, Rhonda L Bitting, Michael J Pishvaian, Branimir I Sikic, Naiyer A Rizvi, Julie E Bauman, Thomas Kaley, Fabio Iwamoto, Joachim M Baehring, Jeanny B Aragon-Ching, Thomas R Hawthorne

Get full text